Olaparib is approved as maintenance therapy in patients with brca mutated platinum sensitive ps recurrent ovarian cancer oc after response to last platinum based therapy. Fda expands approval of olaparib for ovarian cancer. Standard therapy for patients with newly diagnosed advanced ovarian cancer consists of cytoreductive surgery and platinumbased chemotherapy. Olaparib azd2281, mk7339 trade name lynparza is an fdaapproved targeted therapy for cancer. Solo1 the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Niraparib as maintenance therapy in a patient with ovarian. The case for the combination of olaparib lynparza and durvalumab imfinzi in patients with metastatic breast cancer and relapsed ovarian cancer with germlinebrcamutations was strengthened based on. Nct01078662 demonstrated an objective response rate orr of 46% in a small number of patients with platinumsensitive ovarian cancer. Olaparib lynparza olaparib is also called by its brand name lynparza. Study evaluating the efficacy of maintenance olaparib and. Olaparib, a potent oral poly adpribose polymerase inhibitor, exhibits antitumor activity and prevents the recurrence in advanced ovarian cancer.
You have chemotherapy before you start taking olaparib. Role of olaparib as maintenance treatment for ovarian cancer. Group input on olaparib lynparza for ovarian cancer, a summary of submitted provincial advisory group input on olaparib lynparza for ovarian cancer. Olaparib tablets as maintenance therapy in patients with platinumsensitive, relapsed ovarian cancer and a brca12 mutation solo2engotov21. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline brca12 mutation. Ovarian cancer for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic. Lynparza olaparib treatment for advanced ovarian cancer. Olaparib monotherapy in patients with advanced relapsed.
Olaparib azd2281 is a smallmolecule, potent oral parp inhibitor. Durvalumab treatment in combination with chemotherapy and. The nccn guidelines panel for cervical cancer screening endorses the following guidelines for the prevention and early detection of cervical cancer. Niraparib is a poly adenosine diphosphate ribose polymerase inhibitor which uses the concept of synthetic lethality in the presence of a mutation in the breast cancer. Olaparib is a parp inhibitor that has been approved for maintenance for brcamutated ovarian cancer in the recurrent and frontline setting as well as for treatment of brcamutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. Women with newly diagnosed advanced ovarian cancer may benefit from initial treatment with one of several parp inhibitors, according to results from three separate clinical trials. Most patients are diagnosed at advanced stage with poor prognosis.
Olaparib for metastatic breast cancer in patients with a germline brca mutation. Os was slightly increased in ovarian cancer patients with olaparib contrast to placebo or other chemotherapy hr0. Olaparib as maintenance treatment for patients with platinum. It acts against cancers in people with hereditary brca1 or brca2 mutations, which include some ovarian. The initial approval of olaparib in december 2014 by the fda was as monotherapy in patients with deleterious or suspected deleterious germline brcam as detected by an fdaapproved test advanced ovarian cancer. May 22, 2019 the national comprehensive cancer network nccn clinical practice guidelines for ovarian cancer recommend olaparib or niraparib maintenance therapy after partial or complete response to platinum chemotherapy, irrespective of brcam testing. Additional information is available at the end of the chapter. May 03, 20 olaparib maintenance monotherapy in patients with brca mutated ovarian cancer following first line platinum based chemotherapy. Maintenance olaparib in patients with newly diagnosed advanced. Olaparib tablets for maintenance treatment in ovarian cancer. Clinical trials are research studies that involve people.
Olaparib for the treatment of platinumsensitive relapsed ovarian cancer olaparib. Olaparib plus bevacizumab as firstline maintenance in. Olaparib for maintenance treatment of relapsed platinum. It is for people who have a change in a gene called brca. Ovarian cancer, fallopian tube cancer, peritoneal cancer, breast cancer, pancreatic cancer lynparza olaparib. Lynparza approved in eu for the treatment of germline brca. Olaparib parp inhibitor is a new drugoral tablets medicated at the dose of 400mg bdused in the treatment of ovarian cancer patients with present brca mutations in two settings, namely, as maintenance therapy after standard chemotherapy based on paclitaxel and carboplatin has been completed, given after recurrence of platinumsensitive ovarian cancer.
Olaparib lynparza national drug monograph january 2016. It is a parp inhibitor, inhibiting poly adp ribose polymerase parp, an enzyme involved in dna repair. Fda approved olaparib capsules in 2014 for the treatment of patients with deleterious or suspected deleterious germline brcamutated advanced ovarian cancer who have been treated with three or. It acts against cancers in people with hereditary brca1 or brca2 mutations, which include some ovarian, breast, and prostate cancers. Olaparib has shown significant clinical benefit as maintenance therapy in women with newly. People with ovarian cancer would welcome wider availability of olaparib with a more convenient administration schedule 3. Parp inhibitors and quality of life in ovarian cancer. Lynparza is used as maintenance treatment after the cancer has responded to your first treatment with platinumbased chemotherapy. It may be given if a blood test or a test of the tumour shows that you have a genetic mutation called brca1 or brca2. Lynparza, innolaparib european medicines agency europa eu. Genentechroche demonstrated a statistically significant and clinically meaningful improvement in progressionfree survival pfs in women with newlydiagnosed advanced ovarian cancer. The studies tested the parp inhibitors niraparib zejula, olaparib.
Clinical trials look at new ways to prevent, detect, or treat disease. Pdf parp inhibitors in ovarian cancer researchgate. Large genomic rearrangements in the familial breast and ovarian cancer gene brca1 are associated with an increased frequency of high risk features. Olaparib is used to treat some types of ovarian, fallopian tube or primary peritoneal cancer that have come back after other treatments. Ovarian cancer is the leading cause of death from gynecologic tumors in the western world.
Lynparza is a poly adpribose polymerase parp inhibitor indicated. Sep 28, 2019 in paola1, the results of olaparib added to bevacizumab were significant and have the potential to change clinical practice in how women with advanced ovarian cancer are treated in the firstline maintenance setting, raycoquard noted. Maintenance olaparib in advanced ovarian cancer twice daily or. Ovarian cancer is the seventh most common cancer in women worldwide and is the leading cause of death from gynecologic cancers in highincome countries. Treatment of gbrcam her2negative metastatic breast cancer. The first one, approved december 19 th, 2014, was olaparib. As such, parp inhibitors have the potential to be beneficial in a much wider proportion of ovarian cancer patients than was originally proposed. Icon 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinumbased chemotherapy in women with relapsed platinumsensitive ovarian, fallopian tube or peritoneal cancer. Nov 09, 2018 durvalumab treatment in combination with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib treatment in advanced ovarian cancer patients.
Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer. Olaparib plus durvalumab show durable activity in germline. Clinical trials using olaparib national cancer institute. Pdq supportive and palliative care editorial board. Treatment is continued until disease progression or unacceptable. Ovarian cancer is the second the most common gynaecological malignancy in developed countries. Parp inhibitors as initial treatment for ovarian cancer. Olaparib as maintenance therapy in patients with brca 12. Role of olaparib as maintenance treatment for ovarian. Olaparib in patients with recurrent highgrade serous or. Efficacy and safety of olaparib maintenance therapy in. Pdf polyadpribose polymerase inhibitors parpis are the most active and interesting therapies approved for the treatment of epithelial ovarian.
Olaparib in the management of ovarian cancer ovarian symptom index fosi and the trial outcome index t oi have been used to me asure healthre lated qol. Epithelial ovarian cancer oc remains the most lethal gynecologic malignancy. Olaparib name of proposed course of treatment include brief explanation if medical term not clear olaparib for the treatment of ovarian cancer. Olaparib is a parp inhibitor that has been approved for maintenance for brcamutated ovarian cancer in the recurrent and frontline setting as well as for treatment of brcamutated ovarian cancer in. The use of maintenance therapy with olaparib provided a substantial benefit with regard to progressionfree survival among women with newly diagnosed advanced ovarian cancer and a brca12 mutation. Olaparib lynparza cancer information cancer research uk. Olaparib as maintenance treatment for patients with. Olaparib lynparza is a parp inhibitor that can induce synthetic lethality in cancer cells with a deleterious brca mutation. Olaparib versus nonplatinum chemotherapy in patients with. For the management of abnormal cervical screening tests and cancer precursors.
Apr 16, 2019 four trials reported the data concerning os in ovarian cancer with 353 patients in olaparib groups compared to 214 patients in other intervention groups. Olaparib in patients with metastatic castrationresistant. Niraparib is a poly adenosine diphosphate ribose polymerase inhibitor which uses the concept of synthetic lethality in the presence of a mutation in the breast cancer susceptibility gene brca. Request pdf olaparib plus bevacizumab as firstline maintenance in ovarian cancer background.
This approval was based on study 42 which demonstrated an objective response rate of 30% with olaparib. Olaparib maintenance monotherapy in patients with brca. The clinical trials on this list are studying olaparib. American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. Most women with newly diagnosed advanced ovarian cancer have a relapse within. Olaparib, a poly adpribose polymerase parp inhibitor, capitalizes on this concept and is the first drug in its class approved for patients with ovarian cancer. Pdf olaparib for the treatment of ovarian cancer researchgate. Lynparza is used as maintenance treatment after the cancer. On august 17, 2017, olaparib lynparza in tablet form was granted regular approval for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinumbased chemotherapy. Capsules are taken orally twice a day, treatment is supplied every 28 days one cycle. Laboratory tests show that it may help slow the growth of ovarian cancer.
The case for the combination of olaparib and durvalumab in patients with metastatic breast cancer and relapsed ovarian cancer with germline brca mutations was strengthened based on the updated results from the phase iii mediola, which was covered in 2 separate presentations at the 2019 esmo congress. Polyadpribose polymerase parp inhibitors were first reported to specifically kill brca1 or brca2deficient cancer cells in 2005, which is an example of synthetic lethality. Nct01078662 demonstrated an objective response rate orr of 46% in a small number of patients with platinumsensitive ovarian cancer who. Preclinically, this orally active parp inhibitor induces synthetic lethality in cells deficient in brca. The recommended dose of olaparib is 300 mg two 150 mg tablets taken orally twice daily with or without food. The studies tested the parp inhibitors niraparib zejula, olaparib lynparza, and veliparib. In 2014, fda approved olaparib capsules for the treatment of advanced ovarian cancer in patients with inherited brca mutations who have received three or more types of chemotherapy. There is an established increased risk of mdsaml in women with ovarian cancer who have received platinum agents. Olaparib is also called by its brand name lynparza. Olaparib for the treatment of platinumsensitive relapsed ovarian cancer olaparib lynparza capsule formulation received approval based on the results from study 19.
Olaparib is the most studied parp inhibitor to date in ovarian cancer. Ovarian cancer oc is the leading cause of death in women with gynecological cancer. Olaparib displays benefit in clinical trials of brca mutationharboring ovarian and breast cancers as well as prostate, pancreatic, and nonsmall cell lung cancers nsclc. Olaparib is the only agent available in relapsed ovarian cancer that targets those with brca12 mutations olaparib dose is 400 mg eight 50 mg capsules by mouth twice daily for a total. Dnarepair defects and olaparib in metastatic prostate cancer. Fda approves olaparib for germline brcamutated metastatic. Advanced gbrcamutated ovarian cancer treated with 3 or more 17 patient counseling information prior lines of chemotherapy 14. A subgroup analysis of data from a phase ii trial of olaparib monotherapy in patients with a gbrcam study 42. Fda approves olaparib tablets for maintenance treatment in.
Lynparza olaparib phase iii solo2 data demonstrated progressionfree survival benefit in brcamutated ovarian cancer as maintenance therapy published 14 march 2017. A promising parp inhibitor in ovarian cancer therapy. Although the majority of such patients have no evidence of disease. Lynparza olaparib phase iii solo2 data demonstrated. Its given if your cancer has come back relapsed after previously having a type of chemotherapy called platinum chemotherapy. Ovarian cancer for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum based chemotherapy.
In this article, we assessed the efficacy and safety of olaparib maintenance therapy on platinumsensitive ovarian cancer. Bc cancer protocol summary for maintenance treatment of. Ncis basic information about clinical trials explains the types and phases of trials and how they are carried out. Stewart bpharm last updated on jan 1, 2020 fda approved. Olaparib parp inhibitor is a new drugoral tablets medicated at the dose of 400mg bdused in the treatment of ovarian cancer patients with present brca mutations in two settings, namely, as maintenance therapy after standard chemotherapy based on paclitaxel and carboplatin has been completed, given after recurrence of platinumsensitive ovarian cancer, or as the third and. In a study of two doses of olaparib in brcamutant patients with advanced ovarian cancer, both doses were well tolerated and demonstrated modest effect. Parp inhibitors and quality of life in ovarian cancer the. A study of olaparib prior to surgery and chemotherapy in.
1382 1546 1379 887 1022 166 701 769 1123 1501 1350 540 1366 242 1095 58 911 302 163 827 653 1427 242 177 1140 517 122 48 1025 1226 1274 573 1144 437 266 1353 763 1133 1385